USSTOCK.TODAY
Market Closed
Log in Sign up

Soligenix Inc(SNGX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

SNGX
SNGX
Soligenix Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$0.24
-0.01 ▼ -5.06%
Nov 19 at 4:04 PM ET (Korea 11/20 06:04)
$0.24
+0.00 -1.33%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -0.74Insider Own ⓘ 4.59%Shs Outstand ⓘ 23.4MPerf Week ⓘ -25%
Market Cap ⓘ 0.01BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 22.3MPerf Month ⓘ -31.45%
Enterprise Value ⓘ -0.00BPEG ⓘ -EPS next Q ⓘ -0.1Inst Own ⓘ 5.43%Short Float ⓘ 0.3%Perf Quarter ⓘ -40.15%
Income ⓘ -0.01BP/S ⓘ -EPS this Y ⓘ -Inst Trans ⓘ 8.84%Short Ratio ⓘ 0.32Perf Half Y ⓘ -38.46%
Sales ⓘ 0.00BP/B ⓘ 0.9EPS next 5Y ⓘ -ROA ⓘ -85.03%Short Interest ⓘ 0.07MPerf YTD ⓘ -82.09%
Book/sh ⓘ 0.27P/C ⓘ 0.62EPS past 3/5Y ⓘ 69.72% 57.52%ROE ⓘ -127.42%52W High ⓘ -85.84% ($1.70)Perf Year ⓘ -81.82%
Cash/sh ⓘ 0.39P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -137.79%52W Low ⓘ 3.94% ($0.23)Perf 3Y ⓘ -96.25%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 79.77%Gross Margin ⓘ -Volatility(W/M) ⓘ 12.5% 7.94%Perf 5Y ⓘ -99.88%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.02Perf 10Y ⓘ -99.97%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 2.99EPS Q/Q ⓘ 91.36%Profit Margin ⓘ -RSI (14) ⓘ 19.26Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 2.99Sales Q/Q ⓘ -SMA20 ⓘ -27.28% ($0.33)Beta ⓘ 2.1Target Price ⓘ $1.5
Payout ⓘ -Debt/Eq ⓘ 0.04Earnings ⓘ 2026/11/6SMA50 ⓘ -31.29% ($0.35)Rel Volume ⓘ 0.73Prev Close ⓘ $0.25
Employees ⓘ 14LT Debt/Eq ⓘ 0.02EPS/Sales Surpr. ⓘ 52.38% -SMA200 ⓘ -60.67% ($0.61)Avg Volume(3M) ⓘ 0.21MPrice ⓘ $0.24
IPO ⓘ 1994/4/4Option/Short ⓘ No/YesTrades ⓘ 340Volume ⓘ 150,768Change ⓘ -5.06%
Company
SNGX SNGXSoligenix Inc | NASD | Biotechnology Deep dive

🧫 Soligenix, Inc. is a clinical-stage biotech that addresses both rare diseases and public health vaccines. Its lead pipeline candidate, HyBryte™, is a photodynamic therapy that activates synthetic hypericin with visible light, targeting cutaneous T-cell lymphoma (CTCL) in an ongoing Phase 3 FLASH2 clinical trial. In its public health division, the company also develops vaccine programs such as RiVax® for biodefense and infectious diseases.

Quote

Over the past 1 year, on the lower side

86% below its 1-year high.

Now $0.24
52w low$0.2352w high$1.70
52W Range1%
Volume ⓘ 150,768

Traded less than usual. That is 73% of its average volume.

D
Overall · many cautions
We judged 4 of the 8 questions below. 3 need caution.
No data for growth, valuation, outlook, dividends, or not applicable.
ETFs holding this stock 1 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #535 of 598 in the industry

Based on market cap of $6M.

FAQ

FAQ

What kind of company is SNGX?

SNGX belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of SNGX?

The market cap of SNGX is approximately $6M, ranking 5,536 within its sector.

What is the 52-week high and low for SNGX?

SNGX has recorded a 52-week high of $1.70 and a low of $0.23.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels